Actively Recruiting
Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure
Led by South West Sydney Local Health District · Updated on 2024-04-17
70
Participants Needed
1
Research Sites
236 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with coronavirus disease (COVID) and non-COVID acute respiratory failure (ARF) may be at an increased risk of thrombosis due to increased clot formation and decreased clot lysis. This two stage study aims to utilise bedside coagulation technology to detect patients at increased risk and guide tPA treatment to maximise efficacy and safety through a personalised approach.
CONDITIONS
Official Title
Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Acute respiratory failure with hypoxemia defined by PaO2/FiO2 ratio ≤ 300 mmHg and PEEP ≥ 5 cm H2O
- Admission to intensive care
- Age between 18 and 75 years
- Procoagulant blood profile on ClotPro fibrinogen or extrinsic coagulation tests showing elevated amplitude or clot firmness
- Lysis time on ClotPro tissue plasminogen activator test equal to or greater than 365 seconds
You will not qualify if you...
- Platelet count below 150 x 10^9/L or decrease of 50% or more in last 24 hours
- Body weight less than 60 kg
- Structural intracranial disease such as arteriovenous malformation or aneurysm
- Previous intracranial hemorrhage
- Ischemic stroke within past 3 months
- Traumatic cardiopulmonary resuscitation
- Hypoxemia caused by traumatic lung injury
- Active or recent bleeding
- Recent surgery, trauma, or invasive procedure
- Systolic blood pressure above 180 mm Hg
- Diastolic blood pressure above 100 mm Hg
- Pericarditis or presence of pericardial fluid
- Diabetic retinopathy
- Currently menstruating
- Pregnancy (beta-HCG test required if of child-bearing age)
- Severe liver failure or liver enzyme levels 5 times above normal
- Kidney failure with eGFR ≤ 30 mL/hr or receiving dialysis
- Use of therapeutic anticoagulants or platelet blockers
- Not receiving active treatment
- Unlikely to survive beyond the next day
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Intensive Care Unit, Liverpool Hospital, South Western Sydney Local Health District
Liverpool, New South Wales, Australia, 1871
Actively Recruiting
Research Team
A
Anders Aneman
CONTACT
L
Lucy Coupland
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here